Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314639 | 1.00 | KDM4E (0.40) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL30993068 | 0.88 | LSS (0.40) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL120011 | 0.82 | APP (0.40) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL1284075 | 0.82 | KDM4E (0.42) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL456392 | 0.82 | KDM4E (0.46) | KDM4EGABRA5GBA1LSS | |
| SCHEMBL3453968 | 0.82 | KDM4E (0.39) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL23720317 | 0.81 | LSS (0.39) | KDM4EGABRA5GBA1LSS | |
| SCHEMBL3056766 | 0.80 | KDM4E (0.41) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL2468915 | 0.80 | KDM4E (0.41) | KDM4EGABRA5GBA1ALDH1A1LSS | |
| SCHEMBL256028 | 0.80 | PIK3CD (0.43) | KDM4EGABRA5GBA1ALDH1A1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115960082-B | Tetra-substituted olefin compound, preparation method thereof and application thereof in medicine | 长春金赛药业有限责任公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-115960082-A | Tetra-substituted olefin compound, preparation method and medical application thereof | 长春金赛药业有限责任公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885GABRA5 1806/4885GBA1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.